SCOPE 2025, held from February 3-6 in Orlando, Florida, brought together over 4,500 leaders in clinical operations and research to discuss the latest advancements in clinical trial innovation, planning, management, and operations. The TriNetX team was in full force, actively engaging attendees and showcasing solutions aimed at optimizing the “last mile” in clinical research—where protocols are implemented, and patient engagement becomes paramount.
Additionally, TriNetX experts took to the podium to share perspectives and insights on the future of clinical trials. Akiko Shimamura, SVP of Trial Design & Optimization at TriNetX, spoke about putting patients at the heart of research to enhance the relevance and impact of clinical studies. Samantha Shaw, Director of Product Management at TriNetX, participated in a panel discussion on the challenges with diversity data and the steps needed to bridge gaps for more inclusive and accurate research outcomes.
In an interview with Shaw, we delved into the top three takeaways from this year’s conference:
1. Emphasis on Diversity in Clinical Trials
Q: How was the topic of diversity addressed at SCOPE?
A: Diversity was a prominent theme throughout the conference. Discussions highlighted the challenges and strategies in promoting inclusivity within clinical trials. A notable point was the observation that while the Food and Drug Administration (FDA) has removed previously issued draft guidance on diversity in clinical trials from its website, many in the industry remain committed to its principles, recognizing the intrinsic value of diverse participation. An insightful perspective shared was that efforts should extend beyond merely removing barriers; the goal should be to actively welcome and encourage diverse populations to participate in clinical trials. This approach shifts the focus from passive inclusion to proactive engagement.
2. Integration of Artificial Intelligence (AI) in Clinical Research
Q: What role did AI play in the discussions?
A: AI was a significant focus at SCOPE, permeating various tracks and sessions. Organizations showcased a spectrum of approaches to AI integration. Some are in the exploratory phase, developing frameworks to understand potential applications, while others are actively implementing AI solutions. For instance, one organization is utilizing Monte Carlo simulations to assess the impact of modifying inclusion and exclusion criteria on trial feasibility, conducting thousands of iterations to optimize study design. Another example involved using AI to recommend trial sites based on past performance and to predict enrollment timelines, thereby enhancing planning accuracy. The diverse applications of AI underscore its potential to revolutionize various aspects of clinical trials.
3. Commitment to Patient-Centricity
Q: How was patient-centricity emphasized during the conference?
A: Patient-centricity was a recurring theme, with numerous discussions centered on understanding and improving the patient experience in clinical trials. Speakers and attendees shared personal stories of participating in trials, shedding light on factors that influence patient decisions to enroll and remain in studies. Common challenges highlighted included the need for better communication and feedback mechanisms during trials. Discussions also touched on the importance of diversity among clinical trial staff, suggesting that patients might feel more comfortable and willing to participate when approached by individuals with whom they can relate. This insight points to the broader need for representation and cultural competence within research teams to foster trust and engagement.
Looking Ahead: The Future Impact on Clinical Trials
Q: Which of these takeaways do you believe will have the most significant impact on clinical trials in the next five years?
A: The integration of AI stands out as a transformative force. The willingness of organizations to experiment with AI applications, learn from failures, and iterate on solutions is poised to drive substantial advancements in trial efficiency and effectiveness. This adaptive mindset, coupled with technological innovation, is expected to significantly shape the future landscape of clinical research.
Applying Insights to TriNetX’s Mission
Q: How do you envision these conference takeaways influencing your work at TriNetX?
A: These takeaways offer valuable perspectives for TriNetX. Identifying potential partnerships and considering the adoption of proven AI use cases can enhance our capabilities. For example, the Monte Carlo simulation approach to evaluating inclusion and exclusion criteria aligns with our goal of optimizing study design. By supporting such methodologies, we can better assist our clients in conducting efficient and inclusive clinical trials.
Improving Clinical Trial Outcomes
SCOPE 2025 underscored the industry’s dedication to embracing diversity, leveraging AI, and prioritizing patient-centric approaches. These focal points are set to drive innovation and improvement in clinical trials, ultimately leading to more effective and inclusive healthcare solutions.
TriNetX remains at the forefront of this transformation, continuously enhancing its real-world data (RWD) capabilities and AI-driven analytics to support clinical trial optimization. By providing researchers and sponsors with advanced tools for site selection, patient recruitment, and study feasibility, TriNetX is not only enabling faster, more efficient trials but also fostering greater inclusivity in research. As the industry shifts towards more patient-focused and technology-driven approaches, TriNetX is committed to leading the charge.
Boost your clinical trial success—gain expert insights to overcome challenges and accelerate trial completion. Register now for our live webinar March 19, 2025.
